Drug Trial Radar · NCT05731544
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
443
Actual
Start
Aug 17, 2022
Primary completion
Nov 18, 2024
Study completion Jul 8, 2025
Sponsor
- Lead sponsor
- Biomea Fusion Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
Conditions
- Type 2 Diabetes Mellitus
Interventions
BMF-219Drug
Investigational Product
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety AssessmentsTime frame: 52 weeks
- Pharmacokinetics AssessmentsTime frame: 12 weeks
- Change in HbA1cTime frame: 26 weeks
Locations
39 sites in 2 countries. Site status is shown where the registry gives one.
Hope Clinical Research
Canoga Park, California
Ark Clinical Research, LLC
Fountain Valley, California
Velocity Clinical Research
La Mesa, California
Ark Clinical Research
Long Beach, California
Catalina Research Institute, LLC
Montclair, California
Metro Clinical Trials
San Bernardino, California
Southwest General Healthcare Center
Fort Myers, Florida
G+C Research Group
Hialeah, Florida
Sunbright Health Research Centers
Homestead, Florida
Avantis Clinical Research
Miami, Florida
Century Research LLC
Miami, Florida
Entrust Clinical Research
Miami, Florida
Panax Clinical Research
Miami Lakes, Florida
David Kavtaradze MD, Inc
Cordele, Georgia
Privia Medical Group
Savannah, Georgia
Cedar Crosse Research Center
Chicago, Illinois
IMA Clinical Research St. Louis
St Louis, Missouri
Santa Rosa Medical Centers of Nevada
Las Vegas, Nevada
Omera Health
Brooklyn, New York
IMA Clinical Research Manhattan
New York, New York
Carolina Research Center
Shelby, North Carolina
Wake Forest Health Network, LLC, Medical Plaza
Winston-Salem, North Carolina
Diabetes and Endocrinology Associates of Stark County
Canton, Ohio
Medical Care, LLC
Elizabethton, Tennessee
IMA Clinical Research
Austin, Texas
Velocity Clinical Research
Dallas, Texas
Zenos Clinical Research
Dallas, Texas
Synergy Groups Medical LLC
Houston, Texas
Synergy Group Medical
Houston, Texas
Synergy Group Medical
Missouri City, Texas
Clinical Trials of Texas, LLC
San Antonio, Texas
Diabetes & Glandular Disease Clinic, P.A.
San Antonio, Texas
Simcare Medical Research
Sugar Land, Texas
Velocity Clinical Research
Waco, Texas
Velocity Clinical Research
Jordan, Utah
Manassas Clinical Research
Manassas, Virginia
BioPharma Services Inc.
Toronto, Canada
BC Diabetes
Vancouver, British Columbia, Canada
Centricity Research LMC
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.